Pfizer Waiting On Macugen: “Stay Tuned,” CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer has not received any comments from FDA about issues with the pending ophthalmic agent Macugen, the company told analysts Nov. 30 in Groton, Conn